Ketogenic Dietary Interventions in ADPKD (23 Nov 2022) | Pei; Weimbs | 2022 PKD Summit

Dr. Pei and Dr. Weimbs discuss their upcoming clinical trial to test the long-term outcomes of ketogenic dietary interventions in ADPKD. The planned trial will be conducted at the University of Toronto by Dr. Pei and his team. Dr. Pei is a prominent nephrologist and PKD researcher at the University of Toronto. The clinical trial is supported in part by the Canadian Institutes of Health Research and Santa Barbara Nutrients, a company founded by University of California Santa Barbara professor and PKD researcher Thomas Weimbs. The trial is also a collaboration with the Ren.Nu dietary program for ADPKD that is led by renal dietitian Jessianna Saville and her team. ADPKD patients in this trial will learn how to implement a plant-focused ketogenic diet together with Santa Barbara Nutrients' medical food KetoCitra, and will then be followed for a year to assess feasibility, tolerability, effects on metabolism, body weight, pain levels, and changes in renal function and total kidney volume. There will be a Q&A session after the discussion, so please ask all of your questions.

York Pei, MD, FRCP(C), FACP, FASN, is a Professor of Medicine from the Division of Nephrology at the University of Toronto; a Senior Scientist from the Toronto General Research Institute, University Health Network; and the Director of the Centre for Innovative Management of Polycystic Kidney Disease, University Health Network. His research has mainly focused on identifying the genetic factors involved in the initiation or progression of genetic kidney diseases as a target for developing novel diagnostic tests and therapies. His research program focuses on genetic, genomic, and translational research of hereditary kidney diseases with a major focus on autosomal dominant polycystic kidney disease (ADPKD). He also made important contributions to genetic research of other hereditary kidney diseases, including familial IgA nephropathy, familial nephrotic syndrome, and Alport syndrome. He has published over 150 peer-reviewed articles, has collaborated widely with researchers nationally and internationally, and has trained numerous clinical and research fellows in hereditary kidney disease. He founded the Centre for Innovative Management for Polycystic Kidney Disease in 2015 which provides advanced diagnostic and novel therapeutics for ADPKD. More than 500 patients are currently followed or co-managed at the centre with over 95% of them involved in at least one research project.

Dr. Pei was the co-recipient of the Lillian Jean Kaplan International Prize for polycystic kidney disease in 2019 and the recipient of the Medal for Research Excellence by the Kidney Foundation of Canada in 2020.

Thomas Weimbs is a professor at the University of California in Santa Barbara (UCSB) where he directs a research laboratory focused on polycystic kidney disease (PKD). He received his doctoral degree from the University of Cologne, Germany, and then conducted postdoctoral research at the University of California in San Francisco. In 1999, he started his first independent research laboratory at the Lerner Research Institute of the Cleveland Clinic as an assistant professor. There, he started to research PKD after he was approached by a local family affected by PKD who financially supported PKD research in his newly-founded laboratory. Their family foundation still supports PKD research in Dr. Weimbs’ lab today. In 2005, Dr. Weimbs moved his laboratory back to California to join the Department of Molecular, Cellular, and Developmental Biology at UCSB.

His laboratory studies molecular mechanisms underlying PKD with an emphasis towards developing new therapies. Research from Dr. Weimbs’ lab has led to a better understanding of PKD and led to novel methods to deliver therapeutics specifically to polycystic kidneys. Some of the most recent research has led to the discovery that dietary interventions and natural metabolites strongly slow PKD progression in animal models. This led to the launch of Santa Barbara Nutrients with the goal to make these approaches available for the nutritional management of PKD and to support kidney health.